Mitochondrial metabolic reprogramming in diabetic kidney disease

被引:3
|
作者
Fan, Xiaoting [1 ]
Yang, Meilin [2 ]
Lang, Yating [2 ]
Lu, Shangwei [2 ]
Kong, Zhijuan [2 ]
Gao, Ying [2 ]
Shen, Ning [1 ]
Zhang, Dongdong [2 ]
Lv, Zhimei [1 ,2 ]
机构
[1] Shandong Univ, Shandong Prov Hosp, Dept Nephrol, Jinan 250021, Shandong, Peoples R China
[2] Shandong First Med Univ, Dept Nephrol, Shandong Prov Hosp, Jinan 250021, Shandong, Peoples R China
来源
CELL DEATH & DISEASE | 2024年 / 15卷 / 06期
基金
中国国家自然科学基金;
关键词
FATTY-ACID OXIDATION; PROXIMAL TUBULE; INHIBITORS; GLUCOSE; NEPHROPATHY; CHOLESTEROL; PODOCYTES; DYNAMICS; FIBROSIS; FISSION;
D O I
10.1038/s41419-024-06833-0
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Diabetic kidney disease, known as a glomerular disease, arises from a metabolic disorder impairing renal cell function. Mitochondria, crucial organelles, play a key role in substance metabolism via oxidative phosphorylation to generate ATP. Cells undergo metabolic reprogramming as a compensatory mechanism to fulfill energy needs for survival and growth, attracting scholarly attention in recent years. Studies indicate that mitochondrial metabolic reprogramming significantly influences the pathophysiological progression of DKD. Alterations in kidney metabolism lead to abnormal expression of signaling molecules and activation of pathways, inducing oxidative stress-related cellular damage, inflammatory responses, apoptosis, and autophagy irregularities, culminating in renal fibrosis and insufficiency. This review delves into the impact of mitochondrial metabolic reprogramming on DKD pathogenesis, emphasizing the regulation of metabolic regulators and downstream signaling pathways. Therapeutic interventions targeting renal metabolic reprogramming can potentially delay DKD progression. The findings underscore the importance of focusing on metabolic reprogramming to develop safer and more effective therapeutic approaches.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Mitochondrial Dysfunction and Metabolic Reprogramming in Chronic Kidney Disease
    Li, Ying
    Hai Pham
    Singh, Prabhleen
    [J]. FASEB JOURNAL, 2019, 33
  • [2] Metabolic reprogramming: A novel therapeutic target in diabetic kidney disease
    Wang, Mengdi
    Pang, Yanyu
    Guo, Yifan
    Tian, Lei
    Liu, Yufei
    Shen, Cun
    Liu, Mengchao
    Meng, Yuan
    Cai, Zhen
    Wang, Yuefen
    Zhao, Wenjing
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [3] Metabolic reprogramming in polycystic kidney disease
    Priolo, Carmen
    Henske, Elizabeth P.
    [J]. NATURE MEDICINE, 2013, 19 (04) : 407 - 409
  • [4] Metabolic reprogramming in polycystic kidney disease
    Carmen Priolo
    Elizabeth P Henske
    [J]. Nature Medicine, 2013, 19 : 407 - 409
  • [5] Metabolic reprogramming heterogeneity in chronic kidney disease
    Miguel, Veronica
    Kramann, Rafael
    [J]. FEBS OPEN BIO, 2023, 13 (07): : 1154 - 1163
  • [6] Targeting Metabolic Reprogramming in Polycystic Kidney Disease
    Boletta, Alessandra
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024,
  • [7] In situ Metabolomics of Metabolic Reprogramming Involved in a Mouse Model of Type 2 Diabetic Kidney Disease
    Linnan, Bai
    Yanzhe, Wang
    Ling, Zhang
    Yuyuan, Liu
    Sijia, Chen
    Xinmiao, Xie
    Fengqin, Li
    Xiaoxia, Wang
    [J]. FRONTIERS IN PHYSIOLOGY, 2021, 12
  • [8] Mitochondrial Regulation of Diabetic Kidney Disease
    Galvan, Daniel L.
    Mise, Koki
    Danesh, Farhad R.
    [J]. FRONTIERS IN MEDICINE, 2021, 8
  • [9] Mitochondrial dysfunction in diabetic kidney disease
    Josephine M. Forbes
    David R. Thorburn
    [J]. Nature Reviews Nephrology, 2018, 14 : 291 - 312
  • [10] Mitochondrial dysfunction in diabetic kidney disease
    Wei, Pascal Zhongping
    Szeto, Cheuk Chun
    [J]. CLINICA CHIMICA ACTA, 2019, 496 : 108 - 116